News - Novo Nordisk


Current filters:

Novo Nordisk

Popular Filters

30 to 54 of 130 results

Sanofi latest to be implicated Chinese bribery allegations


In the wake of allegations that several multinational pharma companies have engaged in unlawful marketing…

Asia-PacificLegalLundbeckMarkets & MarketingNovo NordiskPharmaceuticalSanofi

Novo Nordisk first-half boosted by Victoza and modern insulins


Danish insulin giant Novo Nordisk (NOV: N) posted second quarter 2013, showing that earnings before interest…

DiabetesFinancialNovo NordiskPharmaceutical

Tentative FDA clearance for generic copy of Novo Nordisk diabetes product


US drugmaker Perrigo (Nasdaq: PRGO; TASE) says it has received tentative approval from the US Food &…

DiabetesGenericsNorth AmericaNovo NordiskPerrigoPrandinRegulation

Lilly and Boehringer Ingelheim's basal insulin MAA accepted by EMA


US drug major Eli Lilly (NYSE: LLY) and family-owned German pharma firm Boehringer Ingelheim today (July…

Boehringer IngelheimDiabetesEli LillyLantusNovo NordiskPharmaceuticalSanofiVictoza

Negative US patent ruling for Novo Nordisk on Prandin


Denmark-based insulin giant Novo Nordisk (NOV: N) says that the US Court of Appeals for the Federal Circuit…

DiabetesGenericsLegalNovo NordiskPatentsPharmaceuticalPrandin

Data on Novo Nordisk's Victoza further supporting safety presented at expert workshop


Danish Insulin giant Novo Nordisk (NOV: N) presented data further supporting the safety of Victoza (liraglutide…

DiabetesNovo NordiskPharmaceuticalResearchVictoza

Novo Nordisk files Tresiba/Victoza combo IDegLira for EU approval


Danish insulin giant Novo Nordisk (NOV: N) said today (May 31) that it has submitted a marketing authorization…

DiabetesEuropeIDegLiraNovo NordiskPharmaceuticalRegulationTresibaVictoza

Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial


Danish insulin giant Novo Nordisk (NOV: N) has released headline results from a 56-week double-blind…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearchVictoza

Novo A/S acquires Norway's Xellia Pharmaceuticals in $700 million deal


Denmark-based Novo A/S, the holding company of the Novo Group and the major shareholder in Novo Nordisk…

Antibiotics and Infectious diseasesGenericsMergers & AcquisitionsNovo A/SNovo NordiskPharmaceuticalXellia Pharmaceuticals

Positive Ph III results for Novo Nordisk's FIX derivative for hemophilia B


Danish insulin giant Novo Nordisk (NOV: N) says it has completed paradigm 2, the first Phase III trial…

N9-GPNovo NordiskPharmaceuticalResearch

Strong first-quarter growth from Novo Nordisk and Lundbeck


This morning saw the announcement of first-quarter 2013 financial results from Denmark's two leading…

FinancialLundbeckNovo NordiskPharmaceutical

Emisphere earns $10 million on amended deal with Novo Nordisk


USA-based Emisphere Technologies (OTCBB: EMIS) says that it has agreed with Danish insulin giant Novo…

DiabetesEmisphereLicensingNovo NordiskPharmaceuticalResearch

Briefs: Elan tender offer; German drug price review; Daiichi Sankyo pays milestone


Ireland-based drugmaker Elan (NYSE: ELN) yesterday reported final results of its modified Dutch auction…

ActemraAmgenAnticalinBayerElanFinancialNovo NordiskPharmaceuticalPradaxaPricingProliaRegulationResearchRocheVictozaXarelto

New study shows Novo Nordisk's Victoza achieves 6% weight loss in type 2 diabetes patients


Danish insulin giant Novo Nordisk (NOVN: N) has released headline results from a 56-week, double-blind…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearchVictoza

Novo Nordisk debuts Tresiba in UK and Denmark


Danish insulin giant Novo Nordisk (NOVN: N) has started the European roll-out of its Tresiba (insulin…

DiabetesEuropeMarkets & MarketingNovo NordiskPharmaceuticalTresiba

Novo Nordisk now ready to launch Tresiba in Japan, following pricing accord


Danish insulin giant Novo Nordisk (NOV: N) yesterday announced that it has received approval of the price…

Asia-PacificDegludecDiabetesMarkets & MarketingNovo NordiskPharmaceuticalPricingTresiba

Blow for Novo Nordisk, as FDA further delays Tresiba and Ryzodeg


Danish insulin giant Novo Nordisk (NOV: N) revealed late Sunday that, on February 8, it received a Complete…

DegludecDiabetesNorth AmericaNovo NordiskPharmaceuticalRegulationRyzodegTresiba

30 to 54 of 130 results

Back to top